Different expression of HER2/neu oncogene in breast carcinoma and in liver metastasis. Description of a case

Tumori

Volumn 92, Issue 6, 2006, Pages 536-539

  Rossi, Elisa ^a   Simoncini, Edda ^a   Valcamonico, Francesca ^a   Marini, Giovanni ^a   Grigolato, Piergiovanni ^a   Dessy, Enrico ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Breast cancer; FISH; HER 2; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BIOPSY; BREAST CARCINOMA; CASE REPORT; CHEMOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; ONCOGENE; ONCOGENE NEU; PROTEIN EXPRESSION;

EID: 33846541376     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200612     Document Type: Article

References (18)

1. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, Nogaret JM, Hertens D, Verhest A, Larsimont D: Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Am J Clin Pathol, 113: 675-682, 2000.
2. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat, 52: 261-288, 1998.
3. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist, 3: 237-252, 1998.
4. Kurokawa H, Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res, 9: 511s-515s, 2003.
5. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol, 20: 1467-1472, 2002.
6. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer, 79: 1220-1226, 1999.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001.
8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20: 719-726, 2002.
9. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 19: 1865-1878, 2001.
10. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, Mallon E, Lee PB: Recommendations for HER2 testing in the UK. J Clin Pathol, 53: 890-892, 2000.
11. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res, 49: 2087-2090, 1989.
12. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat, 71: 67-75, 2002.
13. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol, 195: 422-428, 2001.
14. Masood S, Bui MM: Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech, 59: 102-108, 2002.
15. Ross JS, Fletcher A: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol, 112: S53-67, 1999.
16. Merkelbach-Bruse S, Wardelmann E, Behrens P, Losen I, Buettner R, Friedrichs N: Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol, 27: 1565-1570, 2003.
17. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol, 13: 1036-1043, 2002.
18. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol, 23: 974-979, 1992.